Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell carcinoma development

Fine, 2014, Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification, J. Am. Acad. Dermatol., 70, 1103, 10.1016/j.jaad.2014.01.903 Uitto, 2017, Molecular pathology of the basement membrane zone in heritable blistering diseases: the paradigm of epidermolysis bullosa, Matrix Biol., 57-58, 76, 10.1016/j.matbio.2016.07.009 Nyström, 2013, Collagen VII plays a dual role in wound healing, J. Clin. Invest., 123, 3498, 10.1172/JCI68127 Fine, 2009, Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986–2006, J. Am. Acad. Dermatol., 60, 203, 10.1016/j.jaad.2008.09.035 Montaudié, 2016, Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases, Orphanet J. Rare Dis., 11, 117, 10.1186/s13023-016-0489-9 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Arbiser, 2004, Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma, J. Invest. Dermatol., 123, 788, 10.1111/j.0022-202X.2004.23418.x Pourreyron, 2007, Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression, J. Invest. Dermatol., 127, 2438, 10.1038/sj.jid.5700878 Wang, 2011, Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma, Proc. Natl. Acad. Sci. U. S. A., 108, 17761, 10.1073/pnas.1114669108 Purdie, 2010, No evidence that human papillomavirus is responsible for the aggressive nature of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma, J. Invest. Dermatol., 130, 2853, 10.1038/jid.2010.243 Ng, 2012, Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa, Cancer Res., 72, 3522, 10.1158/0008-5472.CAN-11-2996 Gurtner, 2008, Wound repair and regeneration, Nature, 453, 314, 10.1038/nature07039 Fritsch, 2008, A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy, J. Clin. Invest., 118, 1669, 10.1172/JCI34292 Wang, 2013, Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure, Mol. Ther., 21, 1335, 10.1038/mt.2013.87 Lichtman, 2016, Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis, Wound Repair Regen., 24, 215, 10.1111/wrr.12398 Bochaton-Piallat, 2016, The myofibroblast in wound healing and fibrosis: answered and unanswered questions, F1000 Res., 5, 10.12688/f1000research.8190.1 Goruppi, 2013, Mesenchymal stroma: primary determinant and therapeutic target for epithelial cancer, Trends Cell Biol., 23, 593, 10.1016/j.tcb.2013.08.006 Schäfer, 2008, Cancer as an overhealing wound: an old hypothesis revisited, Nat. Rev. Mol. Cell Biol., 9, 628, 10.1038/nrm2455 Lapouge, 2011, Identifying the cellular origin of squamous skin tumors, Proc. Natl. Acad. Sci. U. S. A., 108, 7431, 10.1073/pnas.1012720108 Page, 2013, The epidermis comprises autonomous compartments maintained by distinct stem cell populations, Cell Stem Cell, 13, 471, 10.1016/j.stem.2013.07.010 Eming, 2009, Interrelation of immunity and tissue repair or regeneration, Semin. Cell Dev. Biol., 20, 517, 10.1016/j.semcdb.2009.04.009 Eming, 2014, Wound repair and regeneration: mechanisms, signaling, and translation, Sci. Transl. Med., 6, 265sr6, 10.1126/scitranslmed.3009337 Nyström, 2015, Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms, EMBO Mol. Med., 7, 1211, 10.15252/emmm.201505061 Odorisio, 2014, Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-β signalling in modifying disease severity, Hum. Mol. Genet., 23, 3907, 10.1093/hmg/ddu102 Breitenbach, 2015, Pseudosyndactyly - an inflammatory and fibrotic wound healing disorder in recessive dystrophic epidermolysis bullosa, J. Dtsch. Dermatol. Ges., 13, 1257 Annicchiarico, 2015, Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa, Medicine (Baltimore), 94, 10.1097/MD.0000000000001528 Esposito, 2016, Autoimmunity and cytokine imbalance in inherited epidermolysis bullosa, Int. J. Mol. Sci., 17, 10.3390/ijms17101625 van der Kooi-Pol, 2014, Host-pathogen interactions in epidermolysis bullosa patients colonized with Staphylococcus aureus, Int. J. Med. Microbiol., 304, 195, 10.1016/j.ijmm.2013.11.012 Nunan, 2014, Clinical challenges of chronic wounds: searching for an optimal animal model to recapitulate their complexity, Dis. Model. Mech., 7, 1205, 10.1242/dmm.016782 Hoste, 2015, Innate sensing of microbial products promotes wound-induced skin cancer, Nat. Commun., 6, 5932, 10.1038/ncomms6932 Bianchi, 2009, HMGB1 loves company, J. Leukoc. Biol., 86, 573, 10.1189/jlb.1008585 Li, 2014, Emerging role of HMGB1 in fibrotic diseases, J. Cell. Mol. Med., 18, 2331, 10.1111/jcmm.12419 Tamai, 2011, PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia, Proc. Natl. Acad. Sci. U. S. A., 108, 6609, 10.1073/pnas.1016753108 Petrof, 2013, Serum levels of high mobility group box 1 correlate with disease severity in recessive dystrophic epidermolysis bullosa, Exp. Dermatol., 22, 417, 10.1111/exd.12152 Darby, 2016, The myofibroblast, a key cell in normal and pathological tissue repair, Cell. Mol. Life Sci., 73, 1145, 10.1007/s00018-015-2110-0 Dugina, 2001, Focal adhesion features during myofibroblastic differentiation are controlled by intracellular and extracellular factors, J. Cell Sci., 114, 3285, 10.1242/jcs.114.18.3285 Desmoulière, 1995, Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar, Am. J. Pathol., 146, 56 Wipff, 2007, Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix, J. Cell Biol., 179, 1311, 10.1083/jcb.200704042 Gascard, 2016, Carcinoma-associated fibroblasts: orchestrating the composition of malignancy, Genes Dev., 30, 1002, 10.1101/gad.279737.116 Midwood, 2016, Tenascin-C at a glance, J. Cell Sci., 10.1242/jcs.190546 Kang, 2015, Membrane-to-nucleus signals and epigenetic mechanisms for myofibroblastic activation and desmoplastic stroma: potential therapeutic targets for liver metastasis?, Mol. Cancer Res., 13, 604, 10.1158/1541-7786.MCR-14-0542 Albrengues, 2015, Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts, Nat. Commun., 6, 10204, 10.1038/ncomms10204 Nucera, 2010, B-RafV600E and thrombospondin-1 promote thyroid cancer progression, PNAS, 107, 10649, 10.1073/pnas.1004934107 Karagiannis, 2012, Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis, Oncotarget, 3, 267, 10.18632/oncotarget.451 Pourreyron, 2012, Wnt5a is strongly expressed at the leading edge in non-melanoma skin cancer, forming active gradients, while canonical Wnt signalling is repressed, PLoS ONE, 7, 10.1371/journal.pone.0031827 Bo, 2013, Upregulation of Wnt5a promotes epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells, BMC Cancer, 13, 496, 10.1186/1471-2407-13-496 Berchtold, 2015, Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma, Cancer Lett., 356, 721, 10.1016/j.canlet.2014.10.020 Gaggioli, 2007, Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells, Nat. Cell Biol., 9, 1392, 10.1038/ncb1658 Küttner, 2013, Global remodelling of cellular microenvironment due to loss of collagen VII, Mol. Syst. Biol., 9, 657, 10.1038/msb.2013.17 Barrientos, 2008, Growth factors and cytokines in wound healing, Wound Repair Regen., 16, 585, 10.1111/j.1524-475X.2008.00410.x Massagué, 2006, The logic of TGFb signaling, FEBS Lett., 580, 2811, 10.1016/j.febslet.2006.04.033 Neuzillet, 2015, Targeting the TGF-β pathway for cancer therapy, Pharmacol. Ther., 147, 22, 10.1016/j.pharmthera.2014.11.001 Cui, 1996, TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice, Cell, 86, 531, 10.1016/S0092-8674(00)80127-0 Knaup, 2011, TGFβ-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa, Anal. Cell. Pathol. (Amst), 34, 339, 10.1155/2011/153108 Martins, 2016, Suppression of TGFβ and angiogenesis by type VII collagen in cutaneous SCC, J. Natl. Cancer Inst., 108, djv293, 10.1093/jnci/djv293 Mittapalli, 2016, Injury-driven stiffening of the dermis expedites skin carcinoma progression, Cancer Res., 76, 940, 10.1158/0008-5472.CAN-15-1348 Vanden Oever, 2016, miR-29 regulates type VII collagen in recessive dystrophic epidermolysis bullosa, J. Invest. Dermatol., 136, 2013, 10.1016/j.jid.2016.05.115 Parker, 2014, Fibrotic extracellular matrix activates a profibrotic positive feedback loop, J. Clin. Invest., 124, 1622, 10.1172/JCI71386 Zhou, 2012, Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts, PLoS One, 7 Jiang, 2014, Diverse roles of miR-29 in cancer (review), Oncol. Rep., 31, 1509, 10.3892/or.2014.3036 Yan, 2015, The role of miR-29b in cancer: regulation, function, and signaling, Onco Targets Ther., 8, 539 Jiang, 2015, Autophagy in cellular metabolism and cancer, J. Clin. Invest., 125, 47, 10.1172/JCI73942 Del Principe, 2013, Fibroblast autophagy in fibrotic disorders, J. Pathol., 229, 208, 10.1002/path.4115 Küttner, 2014, Loss of collagen VII is associated with reduced transglutaminase 2 abundance and activity, J. Invest. Dermatol., 134, 2381, 10.1038/jid.2014.185 Gubbiotti, 2015, Proteoglycans regulate autophagy via outside-in signaling: an emerging new concept, Matrix Biol., 48, 6, 10.1016/j.matbio.2015.10.002 Gubbiotti, 2015, Decorin is an autophagy-inducible proteoglycan and is required for proper in vivo autophagy, Matrix Biol., 48, 14, 10.1016/j.matbio.2015.09.001 Neill, 2012, Decorin: a guardian from the matrix, Am. J. Pathol., 181, 380, 10.1016/j.ajpath.2012.04.029 Neill, 2012, Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible fator 1α, vascular endothelial growth factor-A, and induction of thrombospondin-1 and TIMP3, J. Biol. Chem., 287, 5492, 10.1074/jbc.M111.283499 Järveläinen, 2015, Pivotal role for decorin in angiogenesis, Matrix Biol., 43, 15, 10.1016/j.matbio.2015.01.023 Gubbiotti, 2016, Decorin interacting network: a comprehensive analysis of decorin-binding partners and their versatile functions, Matrix Biol., 55, 7, 10.1016/j.matbio.2016.09.009 Neill, 2016, Decorin as a multivalent therapeutic agent against cancer, Adv. Drug Deliv. Rev., 97, 174, 10.1016/j.addr.2015.10.016 Bi, 2008, Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation, Carcinogenesis, 29, 1435, 10.1093/carcin/bgn141 Bozoky, 2014, Decreased decorin expression in the tumor microenvironment, Cancer Med., 3, 485, 10.1002/cam4.231 Järvinen, 2015, Decorin: a growth factor antagonist for tumor growth inhibition, Biomed. Res. Int., 2015, 654765, 10.1155/2015/654765 Nyman, 2015, Decorin in human colon cancer: localization in vivo and effect on cancer cell behavior in vitro, J. Histochem. Cytochem, 63, 710, 10.1369/0022155415590830 Buraschi, 2013, Decorin causes autophagy in endothelial cells via Peg3, Proc. Natl. Acad. Sci. U.S. A., 110, E2582, 10.1073/pnas.1305732110 Goyal, 2014, Decorin activates AMPK, an energy sensor kinase, to induce autophagy in endothelial cells, Matrix Biol., 35, 42, 10.1016/j.matbio.2014.04.002 Has, 2015, Therapies for inherited skin fragility disorders, Exp. Dermatol., 24, 325, 10.1111/exd.12666 Uitto, 2016, Progress toward treatment and cure of epidermolysis bullosa: summary of the DEBRA International Research Symposium EB2015, J. Invest. Dermatol., 136, 352, 10.1016/j.jid.2015.10.050 Nyström, 2017, Cell therapy for basement membrane-linked diseases, Matrix Biol., 57-58, 124, 10.1016/j.matbio.2016.07.012 Siprashvili, 2016, Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa, JAMA, 316, 1808, 10.1001/jama.2016.15588 Akhurst, 2012, Targeting the TGFβ signalling pathway in disease, Nat. Rev. Drug Discov., 11, 790, 10.1038/nrd3810 Colmenero, 2009, Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C, Am. J. Physiol. Gastrointest. Liver Physiol., 297, G726, 10.1152/ajpgi.00162.2009 Wu, 2016, Losartan attenuates myocardial endothelial-to-mesenchymal transition in spontaneous hypertensive rats via inhibiting TGF-β/Smad signaling, PLoS ONE, 11 Gubinelli, 2010, A case of dystrophic epidermolysis bullosa improved with etanercept for concomitant psoriatic arthritis, Am. J. Clin. Dermatol., 11, 53, 10.2165/1153427-S0-000000000-00000 Annicchiarico, 2016, Canakinumab in recessive dystrophic epidermolysis bullosa: a novel unexpected weapon for non-healing wounds?, Clin. Exp. Rheumatol., 34, 961 Trackman, 2016, Lysyl oxidase isoforms and potential therapeutic opportunities for fibrosis and cancer, Expert Opin. Ther. Targets, 20, 935, 10.1517/14728222.2016.1151003 Infante, 2012, Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors, J. Clin. Oncol., 30, 1527, 10.1200/JCO.2011.38.9346 Golubovskaya, 2014, Targeting FAK in human cancer: from finding to first clinical trials, Front. Biosci. (Landmark Ed), 19, 687, 10.2741/4236 Bauer, 2015, Targeting PI3 kinase in cancer, Pharmacol. Ther., 146, 53, 10.1016/j.pharmthera.2014.09.006 Nitulescu, 2016, Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use (review), Int. J. Oncol., 48, 869, 10.3892/ijo.2015.3306 Deisseroth, 2012, U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis, Clin. Cancer Res., 18, 3212, 10.1158/1078-0432.CCR-12-0653 Albrengues, 2014, LIF mediates proinvasive activation of stromal fibroblasts in cancer, Cell Rep., 7, 1664, 10.1016/j.celrep.2014.04.036